دورية أكاديمية
أعرض في EDS

Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment.

التفاصيل البيبلوغرافية
العنوان: Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment.
المؤلفون: Ylisaukko-Oja T; MedEngine Oy, Helsinki, Finland., Af Björkesten CG; Abdominal Center, Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Eberl A; Abdominal Center, Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Nuutinen H; Division of Gastroenterology, Department of Medicine, Turku University Hospital, Turku, Finland., Jussila A; Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland., Molander P; Abdominal Center, Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Koskela R; Department of Medicine, Division of Gastroenterology, Oulu University Hospital, Oulu, Finland., Blomster T; Department of Medicine, Division of Gastroenterology, Oulu University Hospital, Oulu, Finland., Pajala M; Department of Internal Medicine, Kuopio University Hospital, Kuopio, Finland., Ilus T; Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland., Haiko P; Takeda Oy, Helsinki, Finland., Kovac B; Takeda Oy, Helsinki, Finland., Silvola S; Takeda Oy, Helsinki, Finland., Smith S; MedEngine Oy, Helsinki, Finland., Jokelainen J; MedEngine Oy, Helsinki, Finland., Sipponen T; Abdominal Center, Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
المصدر: Heliyon [Heliyon] 2024 Jun 04; Vol. 10 (12), pp. e32432. Date of Electronic Publication: 2024 Jun 04 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : Elsevier Ltd, [2015]-
مستخلص: Purpose: To analyze treatment persistence and treatment outcomes of vedolizumab as first-line biological treatment in Crohn's disease (CD) and ulcerative colitis (UC) patients in a Finnish real-world setting.
Methods: Observational, retrospective, multi-center chart review study that included adult CD and UC patients initiating vedolizumab as first-line biological treatment between 2014 and 2020.
Results: The cohort consisted of 54 CD and 69 UC patients. At month 12, treatment persistence was 84.9 % in CD and 64.7 % in UC. Most vedolizumab discontinuations (CD, n = 11; UC, n = 26) were due to inefficacy. Discontinuations due to adverse events were rare (n < 5). Efficacy improvements were observed in treatment persistent patients at 12 months vs. baseline in the Harvey-Bradshaw Index (CD, 1.8 vs. 3.9, p = 0.001), Partial Mayo Score (UC, 1.0 vs. 4.9, p < 0.001), Physician's Global Assessment (CD, 0.9 vs. 1.8, p < 0.001; UC, 0.4 vs. 2.1, p < 0.001), along with positive endoscopic and biochemical outcomes. Clinical remission was 90.9 % vs. 63.0 % for CD, and 81.6 % vs. 12.3 % for UC, while corticosteroid use was 15.9 % vs. 53.7 % for CD, and 14.6 % vs. 92.8 % for UC at 12 months and baseline, respectively.
Conclusion: Vedolizumab was associated with improvements in efficacy, endoscopic activity, biochemical parameters, and decreased corticosteroid burden when used as a first-line biological treatment.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Tero Ylisaukko-oja reports financial support was provided by MedEngine Oy. Sarah Smith reports financial support was provided by MedEngine Oy. Jari Jokelainen reports financial support was provided by MedEngine Oy. Paula Haiko reports financial support was provided by Takeda Oy. Anja Eberl reports was provided by Janssen-Cilag SAS. Clas-Göran af Björkesten reports financial support was provided by AbbVie Inc. Clas-Göran af Björkesten reports financial support was provided by Bristol Myers Squibb Co. Clas-Göran af Björkesten reports financial support was provided by Janssen Pharmaceuticals Inc. Clas-Göran af Björkesten reports financial support was provided by Merck Sharp & Dohme Corp. Clas-Göran af Björkesten reports financial support was provided by Pfizer Inc. Clas-Göran af Björkesten reports financial support was provided by Takeda Oy. Clas-Göran af Björkesten reports financial support was provided by Mylan Pharmaceuticals Inc. Clas-Göran af Björkesten reports financial support was provided by Ferring Pharmaceuticals Inc. Clas-Göran af Björkesten reports financial support was provided by Vifor (International) AG. Heikki Nuutinen reports financial support was provided by Takeda Oy. Pauliina Molander reports financial support was provided by AbbVie Oy. Pauliina Molander reports financial support was provided by Bristol Myers Squibb Co. Pauliina Molander reports financial support was provided by Gilead Sciences. Pauliina Molander reports financial support was provided by Janssen-Cilag SAS. Pauliina Molander reports financial support was provided by Orion Corporation. Pauliina Molander reports financial support was provided by Pfizer. Pauliina Molander reports financial support was provided by Sandoz Inc. Pauliina Molander reports financial support was provided by Takeda Oy. Pauliina Molander reports financial support was provided by Tillotts Pharma AG. Pauliina Molander reports financial support was provided by Viatris. Ritva Koskela reports financial support was provided by Pfizer Inc. Ritva Koskela reports financial support was provided by Vifor (International) AG. Ritva Koskela reports financial support was provided by Janssen Pharmaceuticals Inc. Ritva Koskela reports financial support was provided by Takeda Oy. Ritva Koskela reports financial support was provided by Ferring Pharmaceuticals Inc. Taina Sipponen reports financial support was provided by AbbVie Oy. Taina Sipponen reports financial support was provided by Bristol Myers Squibb Co. Taina Sipponen reports financial support was provided by Pfizer. Taina Sipponen reports financial support was provided by Takeda Oy. Taina Sipponen reports financial support was provided by Celltrion, Inc. Taina Sipponen reports financial support was provided by Janssen-Cilag SAS. Tero Ylisaukko-oja reports a relationship with MedEngine Oy that includes: equity or stocks.
(© 2024 The Authors.)
References: Inflamm Bowel Dis. 2018 Mar 19;24(4):742-751. (PMID: 29562277)
Gastrointest Endosc. 2004 Oct;60(4):505-12. (PMID: 15472670)
J Crohns Colitis. 2023 May 3;17(5):706-711. (PMID: 36420953)
Scand J Gastroenterol. 2018 Feb;53(2):158-167. (PMID: 29258369)
J Crohns Colitis. 2016 Dec;10(12):1437-1444. (PMID: 27252400)
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7. (PMID: 26323879)
J Crohns Colitis. 2018 Jan 24;12(2):245-257. (PMID: 29077833)
Crohns Colitis 360. 2023 Sep 22;5(4):otad053. (PMID: 37859629)
Dig Liver Dis. 2022 Sep;54(9):1168-1178. (PMID: 34903497)
N Engl J Med. 1987 Dec 24;317(26):1625-9. (PMID: 3317057)
Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7. (PMID: 29857145)
N Engl J Med. 2013 Aug 22;369(8):699-710. (PMID: 23964932)
J Gastroenterol. 2018 Sep;53(9):1048-1064. (PMID: 29869016)
Gastroenterology. 2002 Feb;122(2):512-30. (PMID: 11832465)
Inflamm Bowel Dis. 2017 Jan;23(1):97-106. (PMID: 27930408)
Therap Adv Gastroenterol. 2022 Mar 8;15:17562848221080793. (PMID: 35282607)
N Engl J Med. 2013 Aug 22;369(8):711-21. (PMID: 23964933)
Aliment Pharmacol Ther. 2023 Aug;58(4):429-442. (PMID: 37322825)
Inflamm Bowel Dis. 2022 Aug 1;28(8):1135-1142. (PMID: 34751766)
BMC Gastroenterol. 2020 Jul 8;20(1):211. (PMID: 32640990)
N Engl J Med. 2009 Nov 19;361(21):2066-78. (PMID: 19923578)
Gastroenterology. 2020 Feb;158(3):562-572.e12. (PMID: 31470005)
Gastroenterology. 2014 Sep;147(3):618-627.e3. (PMID: 24859203)
United European Gastroenterol J. 2020 Nov;8(9):1045-1055. (PMID: 32772830)
Gastroenterology. 2007 Feb;132(2):763-86. (PMID: 17258735)
J Crohns Colitis. 2021 Oct 7;15(10):1694-1706. (PMID: 33786600)
J Crohns Colitis. 2020 May 21;14(4):542-556. (PMID: 31549158)
Sci Rep. 2023 Feb 1;13(1):1816. (PMID: 36725872)
J Crohns Colitis. 2022 Jan 28;16(1):27-38. (PMID: 34402887)
Scand J Gastroenterol. 2021 Aug;56(8):906-913. (PMID: 34154506)
N Engl J Med. 2019 Sep 26;381(13):1215-1226. (PMID: 31553834)
Int J Colorectal Dis. 2021 Nov;36(11):2445-2453. (PMID: 33963913)
Aliment Pharmacol Ther. 2019 Oct;50(8):848-857. (PMID: 31483522)
فهرسة مساهمة: Keywords: Biologic; First-line; Inflammatory bowel disease; Treatment outcomes; Treatment persistence; Vedolizumab
تواريخ الأحداث: Date Created: 20240708 Latest Revision: 20240709
رمز التحديث: 20240709
مُعرف محوري في PubMed: PMC11225725
DOI: 10.1016/j.heliyon.2024.e32432
PMID: 38975101
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-8440
DOI:10.1016/j.heliyon.2024.e32432